Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 7,107.0 | 7,038.0 | 7,022.0 | 9,066.0 | 9,662.0 | 9,991.0 | 10,771.0 | 11,465.0 |
| Revenue growth | 1.0% | 0.2% | -22.5% | -6.2% | -3.3% | -7.2% | -6.1% | -9.6% |
| Cost of goods sold | 7,179.0 | 7,287.0 | 6,695.0 | 5,505.0 | 5,691.0 | 6,144.0 | 6,583.0 | 6,753.0 |
| Gross profit | -72.0 | -249.0 | 327.0 | 3,561.0 | 3,971.0 | 3,847.0 | 4,188.0 | 4,712.0 |
| Gross margin | -1.0% | -3.5% | 4.7% | 39.3% | 41.1% | 38.5% | 38.9% | 41.1% |
| Selling, general and administrative | 256.0 | 226.0 | 75.0 | 2,085.0 | 2,379.0 | 2,514.0 | 2,636.0 | 2,865.0 |
| Research and development | | | | 373.0 | 397.0 | 424.0 | 463.0 | 511.0 |
| EBITA | 129.0 | -46.0 | 508.0 | 1,150.0 | 1,056.0 | 712.0 | 896.0 | 1,049.0 |
| EBITA margin | 1.8% | -0.7% | 7.2% | 12.7% | 10.9% | 7.1% | 8.3% | 9.1% |
| Amortization of intangibles | | | | 45.0 | 48.0 | 53.0 | 58.0 | 60.0 |
| EBIT | 129.0 | -46.0 | 508.0 | 1,105.0 | 1,008.0 | 659.0 | 838.0 | 989.0 |
| EBIT margin | 1.8% | -0.7% | 7.2% | 12.2% | 10.4% | 6.6% | 7.8% | 8.6% |
| Pre-tax income | -328.0 | -475.0 | 252.0 | 822.0 | 549.0 | 525.0 | 568.0 | 924.0 |
| Income taxes | -3.0 | -17.0 | 64.0 | 179.0 | 247.0 | 468.0 | 62.0 | 193.0 |
| Tax rate | 0.9% | 3.6% | 25.4% | 21.8% | 45.0% | 89.1% | 10.9% | 20.9% |
| Earnings from continuing ops | -322.0 | -455.0 | 192.0 | 651.0 | 310.0 | 70.0 | 162.0 | 1,288.0 |
| Earnings from discontinued ops | | | | 710.0 | 64.0 | 137.0 | | |
| Net income | -322.0 | -455.0 | 192.0 | 1,361.0 | 374.0 | 207.0 | 162.0 | 1,288.0 |
| Net margin | -4.5% | -6.5% | 2.7% | 15.0% | 3.9% | 2.1% | 1.5% | 11.2% |
| |
| Diluted EPS | ($2.06) | ($2.48) | $0.92 | $2.93 | $1.23 | $0.27 | $632.82 | $4.79 |
| Shares outstanding (diluted) | 156.0 | 183.2 | 209.0 | 222.0 | 251.7 | 256.6 | 0.3 | 269.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|